Moleculin Biotech, Inc. (MBRX): Price and Financial Metrics


Moleculin Biotech, Inc. (MBRX): $1.51

0.07 (+4.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MBRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MBRX Stock Price Chart Interactive Chart >

Price chart for MBRX

MBRX Price/Volume Stats

Current price $1.51 52-week high $3.99
Prev. close $1.44 52-week low $1.02
Day low $1.41 Volume 67,200
Day high $1.55 Avg. volume 114,942
50-day MA $1.62 Dividend yield N/A
200-day MA $2.06 Market Cap 43.15M

Moleculin Biotech, Inc. (MBRX) Company Bio


Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas.


MBRX Latest News Stream


Event/Time News Detail
Loading, please wait...

MBRX Latest Social Stream


Loading social stream, please wait...

View Full MBRX Social Stream

Latest MBRX News From Around the Web

Below are the latest news stories about Moleculin Biotech Inc that investors may wish to consider to help them evaluate MBRX as an investment opportunity.

Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study

Moleculin Biotech Inc (NASDAQ: MBRX ) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, evaluating Annamycin for relapsed and refractory acute myeloid leukemia (AML). Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2D), subject to final approval of the Safety Review Full story available on Benzinga.com

Benzinga | February 14, 2022

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced preliminary results supporting the successful conclusion of its second Phase 1 trial (MB-105) in Poland evaluating Annamycin for the treatment of relapsed and refractory acute myeloid leukemia (AML), where Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2

Yahoo | February 14, 2022

Moleculin Biotech (MBRX) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) on February 2 and set a price target of $5.00. The company's shares closed last Friday at $1.49, close to its 52-week low of $1.31. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech.

Catie Powers on TipRanks | February 6, 2022

Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | February 1, 2022

Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founder, President, CEO and Chairman, will participate in the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 9:00 AM ET.

Yahoo | January 20, 2022

Read More 'MBRX' Stories Here

MBRX Price Returns

1-mo -5.63%
3-mo 7.09%
6-mo -27.05%
1-year -59.19%
3-year -77.12%
5-year -69.31%
YTD -18.82%
2021 -61.11%
2020 -12.89%
2019 -12.01%
2018 -44.09%
2017 -18.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7502 seconds.